Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
Pancreatic Neoplasms
DRUG: TQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules
Progression-free survival (PFS), The time between the start of treatment and tumorigenesis (in any aspect) progression or death (due to any cause).

The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)
Objective Response Rate (ORR), The proportion of patients whose tumors have shrunk to a prespecified value and are able to maintain the minimum time limit is the sum of the proportion of complete and partial responses., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)|Overall survival (OS), Time from the start of treatment to death (due to any cause)., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)|Duration of Response (DOR), The period between the first diagnosis of CR or PR and the discovery of progressive disease (PD)., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)|Disease Control Rate (DCR), The percentage of cases with remission (PR+CR) and stable lesion (SD) after treatment accounted for the number of evaluable cases., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)|Incidence and severity of adverse events (AEs), The occurrence of all adverse events., The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)|Peak concentration (Cmax), Maximum plasma drug concentration., Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.|Transforming growth factor-beta (TGF-β), The relationship between TGF - β content in plasma and anti-tumor efficacy., Before first dose, 30 minutes after the first dose, pre-dose at Cycle 2 Day 1, pre-dose at the first efficacy assessment, pre-dose at the time of remission at the first efficacy evaluation, and at the time of progression, each cycle is 28 days.|Incidence of immunogenicity (ADA), Incidence of immunogenicity (ADA)., Cycle1, 2, 4, 8: Before injection. 30 and 90 days after the last dose|Time to maximum blood concentration (Tmax), Time to maximum blood concentration., Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.|Area under the time-concentration curve (AUC0-t）, Area under the time-concentration curve, 0-t hours after administration., Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.|The area under the time-concentration curve ranges from 0 to infinity after administration (AUC0-∞), The area under the time-concentration curve ranges from 0 to infinity after administration (AUC0-∞)., Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.|Plasma drug half-life (T1/2), Plasma drug half-life, Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms